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2Abstract
Objectives: Many US hospitals lack Infectious Disease (ID) specialists, which may 
hinder antibiotic stewardship efforts. We sought to compare patient-level antibiotic 
exposure at Veterans Health Administration (VHA) hospitals with and without an on-
site ID specialist, defined as an ID physician and/or ID pharmacist.
Methods:  This retrospective VHA cohort included all acute-care patient-admissions
during 2016. A mandatory survey was used to identify hospitals’ antibiotic 
stewardship processes and their access to an on-site ID specialist. Antibiotic use 
was quantified as days-of-therapy (DOTs) per days-present and categorized based 
on National Healthcare Safety Network definitions. A negative binomial regression 
model with risk adjustment was used to determine the association between 
presence of an on-site ID specialist and antibiotic use at the level of patient-
admissions.
Results: Eighteen of 122 (14.8%) hospitals lacked an on-site ID specialist; there 
were 525,451 (95.8%) admissions at ID hospitals and 23,007 (4.2%) at non-ID sites. 
In the adjusted analysis, presence of an ID specialist was associated with lower total
inpatient antibacterial use (OR 0.92, 95% CI, 0.85-0.99). Presence of an ID specialist
was also associated with lower use of broad-spectrum antibacterials [OR 0.61 (95% 
CI, 0.54-0.70) and higher narrow-spectrum beta-lactam use [OR 1.43 (95% CI, 1.22-
1.67)]. Total antibacterial exposure (inpatient plus post-discharge) was lower among
patients at ID versus non-ID sites [OR 0.92 (95% CI, 0.86-0.99).
Conclusions:  Patients at hospitals with an ID specialist received antibiotics in a 
way more consistent with stewardship principles. The presence of an ID specialist 
may be important to effective antibiotic stewardship.
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3Introduction
Antibiotic resistance is a public health crisis that is largely driven by the use 
of antibiotics. Antibiotic stewardship programs (ASPs) improve antibiotic-prescribing
while also decreasing inappropriate antibiotic use. ASPs are therefore an important 
tool to combat the emergence and spread of antibiotic resistant bacteria.
Randomized-controlled trials demonstrating the effectiveness of ASPs have 
involved interventions led by Infectious Disease (ID) specialists, i.e. an ID physician 
with or without an ID pharmacist [1-6]. However, approximately a quarter of US 
hospitals have no access to on-site ID specialists [7, 8]. Hospitals without on-site ID 
specialists have had success reducing antibiotic use by collaborating with remote ID
specialists [6, 9-11], but it is unclear if ID specialists are a prerequisite for effective 
stewardship.
The Veterans Health Administration (VHA), the largest integrated healthcare 
system in the United States, has been a leader in advancing antibiotic stewardship. 
In 2011, the VHA created a national Antimicrobial Stewardship Taskforce (ASTF) to 
facilitate the implementation of antibiotic stewardship activities [12]. In 2014, the 
VHA enacted a directive that mandated every VHA hospital to develop and maintain
an ASP [13]. This mandate also applied to hospitals where no on-site ID specialist 
was available. 
In this study, we sought to compare the structure, processes and outcomes of
ASPs at VHA hospitals with and without on-site ID specialists two years after the 
VHA directive went into effect. We also aimed to determine whether a patient’s 
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4exposure to antibiotics differed whether or not an ID specialist was present at that 
hospital.
Methods
Ethics
The institutional review board (IRB) of the University of Iowa and Iowa City 
Veterans Health Care System approved this study. Waiver for informed consent was
granted by the IRB for this retrospective cohort.
Comparing stewardship structure and processes at sites with and without 
ID specialists
An ID specialist was defined as a pharmacist or physician who had completed
a formal post-graduate residency or fellowship training program in ID. To identify 
hospitals with an on-site ID specialist, we used data from a mandatory antibiotic 
stewardship survey of all VHA hospitals. This survey was administered by the VHA’s 
ASTF and the Healthcare Analysis and Information Group between 12/30/2015 and 
1/15/2016. The survey was to be completed by an individual at each hospital who 
was knowledgeable about the hospital’s antibiotic stewardship activities. 
The presence of an ID-trained physician with formal post-graduate ID 
fellowship training was determined by a positive response to the following two 
survey questions:
 Does your facility offer an inpatient ID consultation service?
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5 Please provide the number of the Infectious Disease physicians who provide 
clinical services to inpatients at your facility (full-time and part-time).
A pharmacist with formal ID residency training was considered to be present 
at the facility if, per survey responses, the hospital’s designated Antibiotic 
Stewardship Pharmacy Champion had either 1) completed an American Society of 
Health-System Pharmacists (ASHP) accredited specialty residency in Infectious 
Diseases, or 2) had Current Board of Pharmaceutical Specialties (BPS) certification 
in Pharmacotherapy with added Qualifications in Infectious Diseases BCPS-AQID. 
Additional hospital characteristics and antibiotic stewardship processes were 
also extracted from the survey. We assumed responses to the survey reflected 
available resources and stewardship processes in 2016. 
Measuring antibiotic use
A retrospective cohort was created that included all patient-admissions to an 
acute-care bed at a VHA hospital during 2016, the year of the above-mentioned 
survey. Using the Veterans Affairs Informatics and Computing Infrastructure (VINCI),
national administrative data was collected from the VHA’s Corporate Data 
Warehouse. This included data on patient demographics, antibiotic use, and 
comorbidities, as defined by International Classification of Diseases, Ninth Revision 
(ICD-9) and Tenth Revision (ICD-10) codes [14]. Inpatient and post-discharge 
antibiotic use was collected from the bar-coding medication administration record 
(BCMA) and outpatient medication files, respectively. 
Inpatient antibiotics included all antibacterial agents administered via the 
following routes: intravenous, intramuscular, digestive tract (e.g. oral), or 
respiratory tract, as defined by the National Healthcare Safety Network (NHSN) [15].
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6Post-discharge antibiotics included oral outpatient antibacterials dispensed during 
the last three days of a hospitalization or the day following discharge. We assumed 
that all outpatient antibacterials dispensed during this time frame were initiated by 
the patient on the day following discharge and were taken for a duration equal to 
the days-supply of the dispensed prescription [16]. Post-discharge injectable 
antibacterials were not included, because most VHA hospitals use contract, non-
VHA pharmacies to administer outpatient parenteral antimicrobial therapy (OPAT)
[17]. Post-discharge antibacterials administered via the respiratory tract were not 
included, because these were rarely prescribed. All antibiotic classifications were 
based on NHSN definitions (supplemental table 1) [15]. 
For each patient-admission, antibacterial use and time at risk for antibacterial
exposure were summarized as days of therapy (DOT) and days-present, 
respectively. Total antibacterial exposure per admission was defined as inpatient 
DOT (any route of administration) plus post-discharge oral DOT [18].
Statistical analysis
 Continuous variables were compared with the student’s t test, and 
categorical variables were compared with the chi-square test.
Using a patient admission-level analysis, antibacterial use among all patient-
admissions at ID sites was compared to antibacterial use among all patient-
admissions at non-ID sites. First, unadjusted comparisons were made using 
negative binominal generalized estimating equations that only adjusted for intra-
hospital clustering. Next, adjusted comparisons were made by adjusting for intra-
hospital clustering in addition to patient demographics (age, gender, race), obesity, 
service type (e.g. proportion of total days-present on a medical versus surgical 
service), intensive care unit (ICU) versus non-ICU (e.g. proportion of total days-
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7present that were in an ICU), individual comorbidities, immunosuppression status, 
and severity of illness, as measured by the acute physiology and chronic health 
evaluation (APACHE) score. Missing values for the APACHE score were assumed to 
be normal; missing values were uncommon except for albumin and bilirubin 
(supplemental table 2). In all regression models, DOT was the dependent variable, 
and the log of days-present was included as an offset variable to account for the 
time of exposure of each patient-admission.
Certain variables were not included in the adjusted analysis. First, 
adjustments were not made for diagnosis-related groups or infection diagnoses, in 
contrast to prior studies [19, 20]. In one prior study, the infectious syndrome 
diagnosed upon admission was often incorrect [21]; therefore, adjustment for 
diagnoses could eliminate important inter-facility differences in antibacterial use. 
Second, adjustments were not made for VHA hospital complexity, which reflects 
three categories: 1) patient population, 2) clinical services complexity and 3) 
education and research. The hospital complexity variable was not entered into the 
model because it was moderately correlated to the presence of an ID specialist 
(Pearson’s correlation coefficient = ─0.53, p<0.01). Finally, adjustments were not 
made for antibiotic stewardship resources or processes, as the acquisition of these 
resources and implementation of these processes were likely facilitated by the 
presence of an ID specialist. A proportion of hospitals lacked an on-site microbiology
laboratory, which is an important but expensive resource that hospitals may be 
reluctant to establish, regardless of an ID specialist’s recommendations. Therefore, 
a sensitivity analysis was performed excluding hospitals that lacked an on-site 
microbiology laboratory.
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Cary, NC).
Results
There were 18 (14.8%) hospitals without an ID specialist and 104 (85.2%) 
sites with an ID specialist. Nearly all (99.0%) sites with an ID specialist had at least 
one ID physician, who was either part-time (n=20) or full-time (n=83); 1 (1.0%) site 
had an ID pharmacist without any ID physicians. Thirty-nine sites (32.0%) had both 
an ID physician and ID pharmacist.
All 18 sites without an on-site ID specialist reported seeking advice from 
another VHA hospital’s ID physician via telemedicine or electronic consults. The 
frequency of consulting with other hospitals’ ID physicians was not reported.
Sites without an ID specialist were smaller than sites with an on-site ID 
specialist (Table 1) . Sites without an ID specialist were also lower complexity 
facilities and significantly less likely to have an ICU (61.1% vs. 93.3%, p<0.01). An 
on-site microbiology laboratory was present at 83.3% of non-ID and 96.2% of ID 
sites (p=0.07).
Antibiotic stewardship resources and processes
An antibiotic stewardship policy existed at 94.4% and 93.3% of non-ID and ID 
sites, respectively (Table 2). Sites with an on-site ID specialist were significantly 
more likely to report full-time employment equivalents (FTEE) devoted to antibiotic 
stewardship (71.8% vs. 33.3%, p<0.01).
An antibiotic stewardship provider champion was more commonly designated
at sites with on-site ID specialists (94.2% vs. 77.8%, p=0.04), and the provider 
champion was usually an ID physician (87.5%). In comparison, hospital without an 
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9on-site ID specialist had designated the following individuals as the provider 
champion for stewardship: an inpatient internal medicine physician (33.3%), 
another type of provider (27.8%), nobody (22.2%), or a physician administrator 
(16.7%) (Table 2). 
An antibiotic stewardship pharmacist champion was identified at 94.4% and 
96.2% of non-ID and ID sites, respectively. Differences were noted across non-ID 
and ID sites in the proportion of pharmacist champions who had completed a 
general residency training program and/or had sought antibiotic stewardship 
certification (Table 2). 
Antibiotic stewardship processes were frequently used across all sites, as 
shown in Table 3. These processes included prior approval, routine audits, timely 
review of positive blood cultures, and education. While nearly all sites reported an 
annual antibiogram, monitoring antibiotic use as defined daily doses or DOT was 
only performed at 33.3% of non-ID sites and 57.7% of ID sites (p=0.06). 
Description of patient-admission cohort
There were 548,458 patient-admissions during 2016, including 23,007 (4.2%)
at the 18 non-ID hospitals and 525,451 (95.8%) at the 104 ID hospitals. The median 
age of all patient-admissions was 68 years (IQR 61-74); 520,287 (94.9%) were male,
and 389,588 (71.0%) were white. Differences in patient-admission characteristics 
between non-ID and ID sites are shown in Table 4.
Patient admission-level analysis of antibacterial use
Table 5 compares antibacterial exposure between patient-admissions 
(hereafter “patients”) at ID and non-ID hospitals. In unadjusted comparisons, 
differences in total inpatient antibacterial among patients at ID and non-ID hospitals
did not reach statistical significance [OR 0.92 (95% CI, 0.85-1.01)], but in the 
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adjusted analysis, patients at ID sites received fewer total inpatient antibacterials 
[OR 0.92 (95% CI, 0.85-0.99)]. 
In the unadjusted analysis, patients at ID sites received fewer broad-
spectrum antibacterial agents predominantly used for community-acquired 
infections [OR 0.64 (95% CI, 0.56-0.74)), more antibacterial agents predominantly 
used for resistant gram-positive infections [OR 1.22 (95% CI, 1.05-1.42)] and more 
narrow-spectrum beta-lactam agents [OR 1.54 (95% CI, 1.31-1.83)]. However, in the
adjusted analysis, differences were only noted in two drug categories: patients at ID
sites received fewer broad-spectrum antibacterials predominantly used for 
community-acquired infections [OR 0.61 (95% CI, 0.54-0.70)] and more narrow-
spectrum beta-lactam agents [1.43 (95% CI, 1.22-1.67)].
Total antibacterial exposure was lower among patients at ID sites in both the 
unadjusted and adjusted analyses, but the difference only reached statistical 
significance in the adjusted analysis [unadjusted: OR 0.97 (95% CI 0.89-1.06); 
adjusted OR 0.92 (95% CI, 0.86-0.99)].
In a sensitivity analysis that excluded the 7 hospitals without an on-site 
microbiology laboratory, the findings from the adjusted analysis remained largely 
unchanged. Total antibacterial exposure no longer significantly differed among 
patients at ID an non-ID sites, but the OR changed by only 0.02 (0.92 to 0.94, 
supplemental table 3).
Discussion
In this cross-sectional study of patients admitted to 122 VHA acute-care 
hospitals, presence of an on-site ID specialist was independently associated with 
receiving fewer broad-spectrum antibacterials for community-onset infections, more
narrow-spectrum antibacterials, and fewer total antibacterials. These differences 
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were noted in the context of a high degree of antibiotic stewardship implementation
across sites with and without ID specialists.
Core principles of antibiotic stewardship include selecting narrow-spectrum 
agents when feasible, using antibiotics only when necessary, and prescribing 
antibiotics for the shortest effective duration [22]. Based on our findings, it appears 
that these stewardship principles were more broadly applied to patients at hospitals
with ID specialists.
We speculate that ID specialists, which we defined as ID physicians and ID 
pharmacists, may mediate these changes in antibiotic-prescribing through a variety 
of different mechanisms. First, ID physicians who are consulted to see hospitalized 
patients may recommend the use of more narrow-spectrum antibiotics and the 
discontinuation of unnecessary antibiotic therapy. ID pharmacists may provide 
similar feedback through their interactions with prescribers. Second, the presence 
of an ID specialist may help enhance institutional knowledge about optimal 
antibiotic-prescribing. For example, having an ID specialist on-site enables a 
hospital 1) to develop ID training programs for pharmacists and physicians, and 2) 
to provide trainees the opportunity to rotate on an ID service. Trainees exposed to 
ID specialists may be more likely to adopt stewardship principles and, in turn, 
promote these principles to their colleagues. Third, the presence of an ID specialist 
may facilitate the acquisition of stewardship resources and the effective 
implementation of other stewardship processes. Hospital administrators may be 
more willing to provide dedicated FTEEs for stewardship activities if there is a 
specialist with an ID-specific skill set to take on the role. Clinicians may be more 
receptive to feedback on their antibiotic-prescribing when the feedback is coming 
from an ID specialist. Furthermore, ID specialists themselves may help convey the 
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importance of dedicated salary support and other resources that facilitate 
stewardship.
In our cohort, there were some key differences in stewardship resources at ID
and non-ID sites. We chose not to adjust for these differences, because it was 
unclear how many of these differences reflected the influence (or lack thereof) of an
ID specialist—the primary effect we sought to measure. In a sensitivity analysis, we 
excluded sites without an on-site microbiology laboratory, and our findings 
remained largely unchanged. In this sensitivity analysis, the confidence interval for 
total antibacterial exposure (inpatient plus post-discharge)  crossed 1.0—perhaps 
due to the smaller sample size—but the direction of the effect still favored less use 
among patients at ID sites. 
Our finding that antibacterial use was lower among patients at ID versus non-
ID sites contributes to the existing literature that has demonstrated the importance 
of ID specialists in reducing unnecessary antibiotic use [1-6]. A cluster-randomized 
trial evaluated three strategies for ASP implementation across 15 small hospitals 
that lacked on-site ID specialists but had telephone access to remote ID specialists
[6]. Reductions in total and broad-spectrum antibiotics were only achieved in the 
cluster of hospitals that had remote ID specialists both pro-actively monitoring 
microbiologic results and managing antibiotic restrictions. These findings suggest 
that the active involvement of ID specialists, even if not on-site, can be an effective 
approach to stewardship. Other smaller non-randomized studies have found that 
the involvement of remote ID specialists in stewardship activities can reduce 
antibiotic use [9-11, 23]. All non-ID sites in our study’s cohort reported 
communicating with off-site ID specialists, but only one of the sites identified an off-
site ID specialist as their stewardship champion. Based on our personal 
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communication with this specific site, the off-site ID specialist was not actively 
engaged in stewardship activities and was instead responding only to ID consult 
requests. 
Our findings do not suggest that hospitals without on-site ID specialists 
cannot improve antibiotic-prescribing. In fact, a recent crossover trial found that 
hospitals without ID specialists were able to implement prospective audit-and-
feedback and, in turn, reduce antibiotic use [24]. In the VHA cohort we describe, it is
possible that the non-ID hospitals were achieving reductions in antibiotic use that 
could not be detected by our cross-sectional design.
To our knowledge, this is the largest study to evaluate the association 
between the presence of an on-site ID specialist and patients’ antibiotic exposure. It
adds to the growing body of literature demonstrating the benefits that ID specialists
provide to hospitalized patients [25-30]. It also highlights the importance of 
developing and maintaining an ID specialist workforce, a need that is even more 
acute given the recent decline in fellowship applicants to ID physician training 
programs [31].
Several limitations to our study should be acknowledged. First, all survey 
responses were self-reported and were not validated. Many hospitals indicated that 
they were using specific stewardship processes, but we were unable to assess how 
well these processes had been implemented. Such a validation would have been 
challenging, as it would have involved in-depth assessments of all 122 sites. 
Second, it is difficult to measure the isolated effect of having an ID specialist, 
because the ID specialist may influence antibiotic-prescribing in ways that cannot 
be quantified. We have proposed some potential explanations for how an ID 
specialist can have hospital-level effects on antibiotic-prescribing, but these 
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explanations cannot be verified using our data. Third, our evaluation focused solely 
on whether an ID physician or ID pharmacist were present on-site, but this does not 
necessarily indicate their direct involvement in stewardship activities. We were 
unable to measure the time an ID specialist devoted to local stewardship activities, 
which would have been a more direct measurement of ID engagement in ASPs. 
Fourth, given the cross-sectional design of our study, it is unclear whether patterns 
of antibiotic use reflect the influence of the ID specialist versus unrelated effects, 
such as institutional norms. Fifth, our model adjusted for several patient-level 
factors that could be associated with antibiotic use, many of which were included in 
previously published risk-adjustment models [19, 20]. There is no established 
approach for risk-adjustment when assessing antibiotic use with patient admission-
level data, so we acknowledge other approaches may also be valid. Sixth, because 
VHA hospital complexity was correlated with the presence of an ID specialist, we 
were only able to adjust for 2 of its components (i.e. patient population and clinical 
services). It remains unclear if the third component of hospital complexity (i.e. 
educational and research programs) influences antibiotic use. Finally, our estimates 
of total antibiotic exposure did not include post-discharge intravenous antibiotics or 
post-discharge antibiotic use in patients who were transferred to post-acute care 
facilities, such as skilled nursing facilities. We suspect that these situations 
represented a minority of patients who received post-discharge antibiotics.
In conclusion, patients at hospitals with ID specialists received more narrow-
spectrum antibacterials, fewer broad-spectrum antibacterials and fewer total 
antibacterials than patients at hospitals without ID specialists. The wider availability
of ID physicians and ID pharmacists may facilitate improvements in antibiotic-
prescribing that, in turn, may slow the spread of antibiotic resistant bacteria.
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Table 1. Characteristics of 122 VHA hospitals, stratified by the presence of
an on-site ID specialist
On-site 
ID specialists
N=104
No on-site 
ID
specialists
N=18
p-value
Admissions per month, 
mean (SD)
424.4 (244.0) 107.2 (57.6) <0.01
Hospital location, n (%)
Urban
Rural
99 (95.2)
5 (4.8)
10 (55.6)
8 (44.4)
<0.01
Hospital complexity, n (%)1,2
1a, 1b, or 1c
2
3
82 (78.8)
15 (14.4)
7 (6.7)
0
9 (50.0)
9 (50.0)
<0.01
Intensive care unit, n (%) 97 (93.3) 11 (61.1) <0.01
Microbiology laboratory on-
site, n (%)
100 (96.2) 15 (83.3) 0.07
1. The Veterans Health Administration classifies its medical facilities at the 
following levels of complexity: 1a, 1b, 1c, 2, or 3. A hospital’s complexity 
level is based on its patient population, clinical services, education and 
research. The most complex hospitals are level 1a, and the least complex are
level 3. 
2. For this category, a comparison was made between the number of level 1 
facilities versus the number of level 2/3 facilities.
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Table 2. Antibiotic stewardship resources at 122 VHA hospitals, stratified 
by the presence of an on-site ID specialist
Antibiotic stewardship 
resources
On-site ID
specialists
N=104
No on-site ID
specialists 
N=18
p-value
Leadership commitment, n (%)
ASP policy exists 97 (93.3%) 17 (94.4%) 1.00
Any FTEEs dedicated to 
stewardship
74 (71.8%) 6 (33.3%) <0.01
Accountability and drug expertise, n (%)
Stewardship provider champion 98 (94.2%) 14 (77.8%) 0.04
Training of stewardship provider 
champion 
Infectious Diseases
Inpatient IM physician
Physician administrator
Other type of provider1
91 (87.5%)
6 (5.8%)
0
1 (1.0%)
0
6 (33.3%)
3 (16.7%)
5 (27.8%)
<0.01
<0.01
<0.01
<0.01
Stewardship pharmacist 
champion 
100 (96.2%) 17 (94.4%) 0.56
Training of stewardship 
pharmacist champion2 
 General residency3
 ID training4
 Stewardship certification5
80 (76.9%)
40 (38.5%)
42 (40.4%)
9 (50%)
0 
13 (72.2%)
0.02
<0.01
0.01
ASP=antibiotic stewardship program; FTEEs = full-time employment equivalent; 
ID=Infectious Disease; IM=Internal Medicine; OPAT= outpatient parenteral 
antibiotic therapy
1. Other type of provider includes an off-site ID physician (n=1), advanced 
practice nurse (n=1), a nursing home provider (n=1), an outpatient physician
(n=1), and a pulmonologist (n=1).
2. The categories listed are not mutually exclusive. For example, a pharmacist 
may have had general residency training while also earning stewardship 
certification.
3. Completed an accredited general residency accredited by the American 
Society of Health-System Pharmacists or holds a current Board of Pharmacy 
Specialties (BPS)-certification in Pharmacotherapy.
4. Current BPS certification with added qualification in ID and/or completed an 
American Society of Health-System Pharmacists accredited ID-specialty 
residency.
5. Obtained certification in antibiotic stewardship from the Society for Infectious
Diseases Pharmacists (SIDP) or Making a Difference in Infectious Diseases 
Pharmacotherapy (MAD-ID).
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Table 3. Antibiotic stewardship processes at 122 VHA hospitals, stratified 
by the presence of an on-site ID specialist
On-site 
ID specialists
N=104
No on-site 
ID specialists 
N=18
p-value
Antibiotic stewardship interventions, n (%)
Prior approval for targeted 
antibiotics
94 (90.4%) 15 (83.3%) 0.41
Routine audits of targeted 
antibiotics at day 1-21
80 (76.9%) 12 (66.7%) 0.38
Routine audits of targeted 
antibiotics at discharge1
49 (47.1%) 8 (44.4%) 0.83
Blood culture review2 69 (66.4%) 9 (50%) 0.18
Automatic stop orders 80 (76.9%) 15 (83.3%) 0.76
Clinical pathways or 
guidelines for specific 
inpatient conditions
89 (85.6%) 15 (83.3%) 0.73
Monitoring, education and feedback, n (%)
Monitor antibiotic use3 60 (57.7%) 6 (33.3%) 0.06
Submit data to NHSN AU 
option
37 (35.6%) 2 (11.1%) 0.04
Annual antibiogram 102 (98.1%) 18 (100%) 1.00
Education4 75 (72.1%) 11 (61.1%) 0.34
Feedback to groups of 
providers
41 (35.3%) 4 (26.7%) 0.51
ID=Infectious Disease; MRSA=methicillin-resistant Staphylococcus aureus; NHSN AU
option=National Healthcare Safety Network’s Antimicrobial Use and Resistance 
option
1. Routine audits refer to systematic reviews of patient-level use of targeted 
antibiotics at least 3-4 times per week
2. Antibiotic stewardship team reviews positive blood cultures in a timely 
fashion
3. Hospital-level antibiotic use is monitored as DDDs (defined daily doses) 
and/or DOTs (days of therapy).
4. Face-to-face group presentations to educate providers on prudent antibiotic 
prescribing
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Table 4. Characteristics of patient-admissions in VHA acute-care hospitals 
during 2016, stratified by the presence of an on-site ID specialists
Total
N=548,458
On-site 
ID specialists
N=525,451
No on-site 
ID specialists
N=23,007
Age, median (IQR) 68 (61-74) 68 (61-74) 68 (60-76)
Male gender, n (%)1 520,287
(94.9)
498,400 (94.9) 21,887 (95.1)
Race, n (%)
White
Black
Other/missing
389,588
(71.0)
114,208
(20.8)
44,662 (8.1)
370,321 (70.5)
112,121 (21.3)
43,009 (8.2)
19,267 (83.7)
2,087 (9.1)
1,653 (7.2)
Obesity, n (%) 187,372
(34.1)
179,343 (34.1) 8,029 (34.9)
Modified APACHE score, 
median (IQR)2
24 (16-33) 24 (16-33) 24 (16-33)
Comorbidities
Alcohol abuse
CHF
COPD
Dementia
Diabetes
Drug abuse
Liver disease, severe
Neurological disorders, other
Paralysis
PVD
Renal failure
107,371
(19.6)
159,188
(29.0)
210,395
(38.4)
54,406 (9.9)
239,125
(43.6)
78,010
(14.2)
18,875 (3.4)
72,343
(13.2)
16,559 (3.0)
114,745
(21.0)
145,916
(26.6)
102,009 (19.4)
153,082 (29.1)
199,268 (37.9)
52,013 (9.9)
229,100 (43.6)
74,748 (14.2)
18,181 (3.5)
69,565 (13.2)
16,044 (3.1)
110,296 (21.0)
140,265 (26.7)
5,362 (23.3)
6,106 (26.5)
11,127 (48.4)
2,393 (10.4)
10,025 (43.6)
3,262 (14.2)
694 (3.0)
2,778 (12.1)
515 (2.2)
4,449 (19.3)
5,651 (24.6)
Immunosuppressed3 33,737 (6.2) 32,809 (6.2) 928 (4.0)
Admitting service, n (%)
Medicine
Surgery
434,291
(79.2)
114,167
(20.8)
412,461 (78.5)
112,990 (21.5)
21,830 (94.9)
1,177 (5.1)
ICU stay, n (%) 85,990
(15.7)
83,874 (16.0) 2,116 (9.2)
Days-present per admission, 
median (IQR)
4 (2-6) 4 (2-6) 4 (2-6)
Infectious Diagnoses
1
2
23
Biliary tract infection
COPD, acute exacerbation
Intra-abdominal infection
Osteo-articular infection
Pneumonia
Skin and soft tissue infection
Urinary tract infection
4,137 (0.8)
29,065 (5.3)
7,797 (1.4)
9,813 (1.8)
34,694 (6.3)
26,098 (4.8)
35,312 (6.4)
4,025 (0.8)
26,667 (5.1)
7,506 (1.4)
9,476 (1.8)
32,359 (6.2)
24,637 (4.7)
33,690 (6.4)
112 (0.5)
2,398 (10.4)
291 (1.3)
337 (1.5)
2,335 (10.2)
1,461 (6.4)
1,622 (7.1)
Abbreviations: APACHE=Acute Physiology and Chronic Health Evaluation; COPD=chronic obstructive pulmonary 
disease; CHF=congestive heart failure; ID=infectious diseases; ICU=intensive care unit; IQR=interquartile range; 
PVD=peripheral vascular disease
1. If the gender value was missing, it was classified as male.
2. The modified APACHE score does not include comorbidities, as these were adjusted for separately.
3. The immunosuppressed category includes either having a diagnosis of lymphoma, leukemia, HIV/AIDs, or 
organ transplantation during the 12 months prior to admissions OR receipt of an immunosuppressive 
medication, which was defined as follows: prednisone or steroid equivalent at a dose ≥20 mg/day during 
the 30 days prior to admission, chemotherapy within the 30 days prior to admission, or an anti-rejection 
medication, biologic agent or a disease-modifying anti-rheumatic drug (DMARD) within the 3 month prior 
to admission
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Table 5.  Patient admission-level antibiotic use in VHA acute-care hospitals during 2016, stratified by 
the presence of an on-site ID specialist
National Healthcare Safety Network 
(NHSN) antibacterial categories
On-site
 ID
specialists
N=525,45
1
No on-site
 ID
specialists
N=23,007
Unadjusted
comparison2,3
RR (95% CI)
Adjusted 
comparison2,4
RR (95% CI)
Inpatient antibacterial exposure, mean (SE) DOT per 1000 days-present
Broad-spectrum antibacterial 
agents predominantly used for 
community-acquired infections 
Broad-spectrum antibacterial 
agents predominantly used for 
hospital-onset infections
112.9 
(2.9)
104.2 
(2.5)
175.9 
(11.6)
93.1 
(5.5)
0.64 (0.56-0.74)
1.12 (0.99-1.27)
0.61 (0.54-0.70)
1.01 (0.89-1.13)
Antibacterial agents predominantly 
used for resistant gram-positive 
infections
73.8 
(2.1)
60.5 
(4.3)
1.22 (1.05-1.42) 1.09 (0.95-1.26)
Narrow-spectrum beta-lactam 
agents 
77.5 
(2.4)
50.2 
(3.9)
1.54 (1.31-1.83) 1.43 (1.22-1.67)
Total antibacterials1 464.2 
(7.1)
502.9 
(19.3)
0.92 (0.85-1.01) 0.92 (0.85-0.99)
Inpatient + post-discharge antibacterial exposure, mean (SE) DOT per 100 admissions
Total antibacterial exposure 380.7 
(6.3)
391.1 
(15.9)
0.97 (0.89-1.06) 0.92 (0.86-0.99)
Abbreviations: SE = standard error, DOT =  days of therapy, RR = rate ratio, CI = confidence interval. 
1. Total antibacterials include the 4 NHSN antibacterial categories listed plus all other antibacterial agents (supplemental table
1).
2. DOT was the dependent variable, and the log of days-present was included as an offset variable to account for the time of 
exposure of each patient-admission.
3. Unadjusted comparisons were made using negative binominal generalized estimating equations that adjusted for intra-
hospital clustering. 
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4. Adjusted comparisons were made by adjusting for intra-hospital clustering, patient demographics (age, gender, race), 
obesity, service type (e.g. proportion of total days-present on a medical versus surgical service), intensive care unit (ICU) 
versus non-ICU (e.g. proportion of total days-present that were in an ICU), individual comorbidities, immunosuppression 
status, and severity of illness, as measured by the acute physiology and chronic health evaluation (APACHE) score. 
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